Danielle Kerkovich is Recognized
BBDF’s principal scientist, Danielle Kerkovich, recieves recognition for her paper as one of the most read in Molecular Genetics & Genomic Medicine.
BBDF-101 Announcement
We are excited to announce the following major milestone for BBDF! Theranexus, a publicly-traded European pharmaceutical company, has committed the $20 million and expertise necessary to complete the clinical trial and commercialization for our drug discovery, BBDF-101.
Theranexus and Beyond Batten Disease Foundation (BBDF) announce the signing of a worldwide exclusive license for Batten disease drug candidate BBDF-101
- The agreement covers the development and marketing of the drug following a single clinical trial due to begin in 2020.
- If successful, this trial will lead directly to the drug’s approval.
Lyon, 12 December 2019 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, is pleased to announce the signing of an agreement with Beyond Batten Disease Foundation, granting it a worldwide exclusive license to develop and commercialize the drug candidate BBDF-101 for juvenile Batten disease.
Beyond Batten Funded Research Professor Awarded
Congratulations to Marco Sardiello, Ph.D. Assistant Professor Molecular &Human Genetics Department, Baylor College of Medicine and BBDF-funded researcher on winning the 2019 Michael E. DeBakey M.D. Award for Research Excellence. Dr. Sardiello is being recognized for his exemplary work in Batten disease.
We are grateful to his dedication to our families and are thrilled that he has been recognized with this prominent award.
Well done and well deserved!
BE Project – Thank You from the Bensons
BE Project – Thank you from the Bensons from Beyond Batten Disease Foundation on Vimeo.
In 2016, after 8 years of funding research for Batten disease, our research team was ready to take the next steps to advance our discovery of a treatment to slow the progression of Batten disease. As you know, The Be Project was launched to raise $6 million in 24 months in order to validate their findings, create patient registries, and advance a host of other necessary steps to prepare for FDA engagement and clinical trials. And, we did just that. WE DID IT!!! We achieved our goal, and we hope you feel so proud and take ownership in this enormous accomplishment!